ClinicalTrials.gg

Program

zasocitinib

Also written as “Zasocitinib”, “TAK-279” and “NDI-034858 study drug”.

Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Crohn Disease · Hidradenitis Suppurativa · Vitiligo, led by Takeda.

Furthest: phase 3, since Oct 12, 202326 company-led studies, 13 open or runningNext primary completion: Feb 5, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda2613 open or runningphase 3since Oct 12, 2023Jul 19, 2021Feb 5, 2027phase 2 · NCT07244263

Also a collaborator on its studies: nimbus-lakshmi-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Jul 19, 2021.

  1. Mar 15, 2024Phase 3 study in PsoriasisNCT06323356 · 18 enrolled · Japan
  2. Aug 8, 2024Phase 3 study in Plaque PsoriasisNCT06550076 · 2,099 enrolled · United States, Argentina, Australia and more
  3. Oct 31, 20242 phase 3 studies in Arthritis, PsoriaticNCT06671496, NCT06671483
  4. Jan 2, 2025Phase 2 study in Crohn DiseaseNCT06764615 · 192 planned · United States, China, Czechia and more
  5. Jan 21, 2025Phase 1 study in Healthy VolunteersNCT06793943 · 78 enrolled · United States
  6. May 8, 2025Phase 3 study in Plaque PsoriasisNCT06973291 · 606 enrolled · United States, Bulgaria, Canada and more
  7. Aug 5, 2025Phase 2 study in Nonsegmental VitiligoNCT07108283 · 207 enrolled · United States, Canada, China and more
  8. Nov 17, 2025Phase 2 study in Hidradenitis SuppurativaNCT07244263 · 91 enrolled · United States, Australia, Canada and more
  9. Nov 18, 2025Phase 3 study in Plaque PsoriasisNCT07250802 · 210 planned · United States, China, Germany and more
  10. Dec 11, 2025Phase 3 study in Arthritis, PsoriaticNCT07286058 · 1,182 planned · United States, Argentina, Australia and more
  11. Feb 4, 2026Phase 2 study in Crohn DiseaseNCT07403968 · 20 planned · United Kingdom
  12. Aug 4, 2026Phase 3 study in PsoriasisNCT07752108 · 40 planned
  13. Oct 7, 2026Phase 3 study in Arthritis, PsoriaticNCT07871721 · 644 planned
  14. Nov 16, 2026Primary completion moved from 2033-01-24 to 2034-07-03Date moved laterphase 3 · +17 months · NCT07250802

Ahead

  1. Feb 5, 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07244263
  2. Feb 17, 2027Primary completion: phase 2 study in Crohn DiseaseNCT06233461
  3. Mar 26, 2027Primary completion: phase 2 study in Nonsegmental VitiligoNCT07108283
  4. May 18, 2027Primary completion: phase 3 study in Arthritis, PsoriaticNCT06671496

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07871721Arthritis, Psoriatic3Not yet recruitingApr 18, 2030644
NCT07752108Psoriasis3Not yet recruitingMay 30, 202740
NCT07403968Crohn Disease · United Kingdom2RecruitingMar 30, 202820
NCT07286058Arthritis, Psoriatic · United States, Argentina, Australia and more3RecruitingDec 18, 20291,182
NCT07250802Plaque Psoriasis · United States, China, Germany and more3RecruitingJul 3, 2034210
NCT07244263Hidradenitis Suppurativa · United States, Australia, Canada and more2Active, not recruitingFeb 5, 202791
NCT07108283Nonsegmental Vitiligo · United States, Canada, China and more2Active, not recruitingMar 26, 2027207
NCT06973291Plaque Psoriasis · United States, Bulgaria, Canada and more3CompletedApr 22, 2026606
NCT06793943Healthy Volunteers · United States1CompletedMar 11, 202578
NCT06764615Crohn Disease · United States, China, Czechia and more2RecruitingDec 30, 2029192
NCT06671496Arthritis, Psoriatic · United States, Argentina, Australia and more3Active, not recruitingMay 18, 2027601
NCT06671483Arthritis, Psoriatic · United States, Belgium, Bulgaria and more3Active, not recruitingMay 18, 20271,583
NCT06550076Plaque Psoriasis · United States, Argentina, Australia and more3Active, not recruitingAug 5, 20292,099
NCT06323356Psoriasis · Japan3CompletedOct 17, 202518
NCT06290050Healthy Volunteers · United States1CompletedMay 3, 202420
NCT06258265Healthy Volunteers · United States1CompletedJun 25, 2024120
NCT06254950Colitis, Ulcerative · United States, Australia, Belgium and more2Active, not recruitingJul 14, 2026213
NCT06233461Crohn Disease · United States, Australia, Belgium and more2RecruitingFeb 17, 2027268
NCT06111547Healthy Volunteers · China1CompletedJul 23, 202424
NCT06108544Plaque Psoriasis · United States, Argentina, Bulgaria and more3CompletedDec 6, 20241,108
NCT06088043Plaque Psoriasis · United States, Australia, Canada and more3CompletedJan 22, 2025693
NCT05995249Healthy Volunteers · United States1CompletedDec 18, 2023172
NCT05992155Renal Insufficiency · United States1CompletedMay 22, 202424
NCT05976321Hepatic Impairment · United States1CompletedApr 15, 202427
NCT05153148Arthritis, Psoriatic · United States, Czechia, Germany and more2CompletedMay 4, 2023305
NCT04999839Moderate to Severe Plaque Psoriasis · United States, Canada2CompletedAug 19, 2022259

How it is read

Names in the registry

  • “Zasocitinib”, 12 entries
  • “TAK-279”, 12 entries
  • “NDI-034858 study drug”, 4 entries
  • “Zasocitinib (Dose A)”, 1 entry
  • “NDI-034858”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.